Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-SIKE1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SIKE1 also known as Squamous Cell Carcinoma Antigen Recognized by T-cells 3 (SART3) is a protein with a molecular weight of approximately 24 kDa. It inhibits the kinase activity of Tank-Binding Kinase 1 (TBK1) and IκB kinase ε (IKKε) which are critical for the induction of type I interferons and other cytokines in response to viral infections. SIKE1 is primarily expressed in various tissues including the brain and liver though expression levels may vary depending on cellular context.
Biological function summary
SIKE1 interacts with signaling pathways to modulate immune responses. As a negative regulator of the interferon signaling pathway it forms complexes with TBK1/IKKε to suppress excessive immune activation preventing potential tissue damage. By efficiently regulating kinase activity SIKE1 helps maintain balance in immune signaling ensuring proper immune defense while avoiding overactivation.
Pathways
The involvement of SIKE1 extends to the toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like receptor signaling pathways. These pathways play essential roles in detecting and responding to viral pathogens. SIKE1 modulates the activity of TBK1 and IKKε which are central to the aforementioned pathways impacting downstream molecules like IRF3 and NF-kB that drive interferon production and inflammatory responses.
SiKE1's regulatory role relates to conditions characterized by dysregulated immune responses. For instance in viral infections where excessive interferon production occurs SIKE1 can mitigate potential tissue damage by dampening cytokine output. It is also studied in auto-inflammatory disorders where control of cytokine production is important for managing disease severity. Its connection to TBK1 and IKKε further implicates SIKE1 in the context of these immune-related conditions as these kinases are targets for therapeutic intervention in disorders related to immune dysregulation.
